Botulinum-A Toxin Injections Into the Detrusor Muscle Decrease Nerve Growth Factor Bladder Tissue Levels in Patients With Neurogenic Detrusor Overactivity

Journal of Urology

Volumn 175, Issue 6, 2006, Pages 2341-2344

  Giannantoni, Antonella ^b   Di Stasi, Savino M ^c   Nardicchi, Vincenza ^a   Zucchi, Alessandro ^b   Macchioni, Lara ^a   Bini, Vittorio ^a   Goracci, Gianfrancesco ^a   Porena, Massimo ^b  

^a UNIVERSITY OF PERUGIA   (Italy)

^b UNIVERSITY OF PERUGIA   (Italy)

^c UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

bladder; botulinum toxin type A; nerve growth factor; spinal cord injuries

Indexed keywords

BOTULINUM TOXIN A; NERVE GROWTH FACTOR;

ADULT; ARTICLE; BLADDER BIOPSY; BLADDER CAPACITY; BLADDER CATHETERIZATION; BLADDER PRESSURE; BLADDER WALL; CLINICAL ARTICLE; CONTROLLED STUDY; CYSTOMETRY; CYSTOSCOPY; DETRUSOR DYSSYNERGIA; DIAGNOSTIC KIT; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; MALE; NERVE CONDUCTION; NEUROGENIC BLADDER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SENSORY NERVE; TISSUE HOMOGENATE; TISSUE LEVEL; URINE INCONTINENCE; URODYNAMICS;

ADMINISTRATION, INTRAVESICAL; ADULT; BOTULINUM TOXIN TYPE A; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; NERVE GROWTH FACTOR; NEUROMUSCULAR AGENTS; URINARY BLADDER; URINARY BLADDER, NEUROGENIC;

EID: 33646368664     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(06)00258-8     Document Type: Article

References (19)

1. Smith C.P., and Chancellor M.B. Emerging role of botulinum toxin in the management of voiding dysfunction. J Urol 171 (2004) 2128
2. Cayan S., Coskun B., Bozlu M., Acar D., Akbay E., and Ulusoy E. Botulinum toxin type A may improve bladder function in a rat chemical cystitis model. Urol Res 30 (2003) 399
3. Duggan M.J., Quinn C.P., Chaddock J.A., Purkiss J.R., Alexander F.C.G., Doward S., et al. Inhibition of release of neurotransmitters from rat dorsal root ganglia by a novel conjugate of a clostridium botulinum toxin A endopeptidase fragment and erythrina cristagalli lectin. J Biol Chem 277 (2002) 34846
4. de Groat W.D., Kawatani M., Hisamitsu T., Cheng C.L., Ma C.P., Thor K., et al. Mechanisms underlying the recovery of urinary bladder function following spinal cord injury. J Auton Nerv Syst 30 suppl. (1990) 371
5. Steers W.D., Kolbeck S., Creedon D., and Tuttle J.B. Nerve growth factor in the urinary bladder of the adult regulates neuronal form and function. J Clin Invest 88 (1991) 1709
6. Ditunno Jr. J.F., Young W., Donovan W.H., Creasey G., and American Spinal Injury Association. The international standards booklet for neurological and functional classification of spinal cord injury. Paraplegia 32 (1994) 70
7. Stohrer M., Goepel M., Kondo A., Kramer G., Madersbacher H., Millard R., et al., International Continence Society Standardization Committee. The standardization of terminology in neurogenic lower urinary tract dysfunction. with suggestions for diagnostic procedures. Neurourol Urodyn 18 (1999) 139
8. Okragly A.J., and HaakFrendscho M. An acid-treatment method for the enhanced detection of GDNF in biological samples. Exp Neurol 145 (1997) 592
9. Smith C.P., Fraser M.O., Bartho L., deGroat W.C., Chancellor M.B., and Somogyi G.T. Botulinum toxin A inhibits afferent nerve evoked bladder strip contractions. J Urol 167 suppl. (2002) 41 abstract 164
10. Cruz F. Mechanisms involved in new therapies for overactive bladder. Urology 63 (2004) 65
11. Tanner R., Chambers P., Khadra M.H., and Gillespie J.I. The production of nerve growth factor by human bladder smooth muscle cells in vivo and in vitro. BJU Int 85 (2000) 1115
12. Lowe E.M., Anand P., Terenghi G., Williams-Chestnut R.E., Sinicropi D.V., and Osborne J.L. Increased nerve growth factor levels in the urinary bladder of women with idiopathic sensory urgency and interstitial cystitis. Br J Urol 79 (1997) 572
13. Giannantoni A., Di Stasi S.M., Nardicchi V., Macchioni L., Guercini F., Goracci G., et al. Botulinum A toxin intravesical treatment induces a reduction of nerve growth factor bladder tissue levels in patients with neurogenic detrusor overactivity. J Urol 173 suppl. (2005) 330 abstract 1217
14. Steers W.D., Creedon D.J., and Tuttle J.B. Immunity to nerve growth factor prevents afferent plasticity following urinary bladder hypertrophy. J Urol 155 (1996) 379
15. Coderre T.C., Basbaum A.I., and Levine J.D. Neural control of vascular permeability. interactions between primary afferents, mast cells, and sympathetic efferents. J Neurophysiol 62 (1989) 48
16. Smith C.P., Franks M.E., McNeil B.K., Ghosh R., de Groat W.C., Chancellor M.B., et al. Effect of botulinum toxin A on the autonomic nervous system of the lower urinary tract. J Urol 169 (2003) 1896
17. Khera M., Somogyi G.T., Kiss S., Boone T.B., and Smith C.P. Botulinum A toxin inhibits ATP release from bladder urothelium after chronic spinal cord injury. Neurochem Int 45 (2004) 987
18. Chaddock J.A., Purkiss J.R., Duggan M.J., Quinn C.P., Shone C.C., and Foster K.A. A conjugate composed of nerve growth factor coupled to a non-toxic derivative of clostridium botulinum neurotoxin type A can inhibit neurotransmitter release in vitro. Growth Factors 18 (2000) 147
19. Seki S., Sasaki K., Fraser M.O., Igawa Y., Nishizawa O., Chancellor M.B., et al. Immunoneutralization of nerve growth factor in lumbosacral spinal cord reduces bladder hyperreflexia in spinal cord injured rats. J Urol 168 (2002) 2269